FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF C	HANGES	IN E	BENEFICIAL	OWNERSHIP
	U. U				

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	ourden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					1 01	3600	1011 30(11) 0	JI LIIC	invesimen	COII	ipariy Act	01 1340							
1. Name and Address of Reporting Person* KADOCH CIGALL				2. Issuer Name and Ticker or Trading Symbol Foghorn Therapeutics Inc. [FHTX]							Relationship of Reporting Person(s) to Issuer (Check all applicable)								
				t)	C Director	or	X	10% O	wner		
(Last) (First) (Middle) 500 TECHNOLOGY SOUARE					3. Date of Earliest Transaction (Month/Day/Year) 06/21/2022								Officer below)	(give title		Other (below)	specify		
· ·																			
STE 700					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)														X Form filed by One Reporting Person					
CAMBR	IDGE M	ΙA	02139													iled by Moi		One Repo	I
(City)	(S	itate)	(Zip)																
		Tab	le I - Non	-Deriv	ative	e Se	curities	s Ac	quired,	Dis	osed o	f, or Be	nefi	cially	y Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			Execution Date,		Transaction Disposed Code (Instr. 5)		ities Acquired (A) o d Of (D) (Instr. 3, 4				es ally following	Form (D) o	vnership n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership					
							Code	v	Amount	(A) o	(A) or (D) Price		Reported Transact (Instr. 3 a	ction(s)			(Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, if any		Date, T	ransaction of ode (Instr. Derivative		ive ies ed ed nstr.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				c	Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	or	ount nber ires					
Stock Options (Right to buy)	\$13.81	06/21/2022			A		16,000		06/21/202	3 0	6/20/2032	Common Stock	16,	,000	\$0.00	16,00	0	D	

Explanation of Responses:

Remarks:

/s /Allan Reine, M.D., Attorney-in-Fact

** Signature of Reporting Person Date

06/22/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).